“小核酸第一股”圣诺医药首席执行官独家回应华熙生物入股

Core Viewpoint - Saint Nor Pharmaceutical has secured approximately HKD 208.2 million in funding through a subscription agreement with Huaxi Biotechnology, which will become its second-largest shareholder with a 9.44% stake [1][2]. Group 1: Investment and Financial Performance - Huaxi Biotechnology's subsidiary will subscribe to 11.56828 million shares at HKD 12 per share, totaling around HKD 139 million [1]. - The stock price of Saint Nor Pharmaceutical surged by 22.78% on the announcement day, closing at HKD 18.38, and continued to rise, reaching HKD 20.62 the following day, marking a cumulative increase of over 120% in eight trading days [2][3]. - As of mid-2023, Saint Nor Pharmaceutical reported no product sales revenue and incurred a loss of approximately USD 3.4 million, with cash and cash equivalents amounting to USD 6.872 million [5][6]. Group 2: Strategic Partnerships and Future Plans - The funding will primarily be used to advance clinical progress of in-development products and delivery system development, with a focus on leveraging Huaxi's expertise in hyaluronic acid to accelerate the development of small nucleic acid products [2][11]. - Saint Nor Pharmaceutical aims to collaborate with Huaxi Biotechnology on the clinical development and commercialization of the STP705 targeted fat reduction project, which is currently in phase I clinical trials [11][13]. - Huaxi Biotechnology has expressed interest in the small nucleic acid drug sector, viewing it as a promising area for investment and collaboration [11][14]. Group 3: Market Context and Challenges - Saint Nor Pharmaceutical, once a leading player in the small nucleic acid sector, has faced challenges in a changing pharmaceutical landscape, leading to a period of contraction after its initial public offering [3][6]. - Huaxi Biotechnology has experienced a decline in revenue from its core functional skincare segment, with a significant drop in sales reported for 2023 and 2024 [7][8]. - The company is undergoing a strategic transformation from a component supplier to a biotechnology platform, which includes direct investments in innovative drug companies like Saint Nor Pharmaceutical [10][14].